Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Allergan Wins Brimonidine Patent Infringement Case
Allergan has announced that the US District Court for the District of Delaware ruled in favor of Allergan in its patent infringement suit against Exela PharmSci, Exela PharmSci,
Allergan has announced that the US District Court for the District of Delaware ruled in favor of Allergan in its patent infringement suit against Exela PharmSci, Exela PharmSci,
XETA Technologies has been selected by Siemens Enterprise Networks to provide technical support services for the US operations of a global pharmaceutical company. XETA provides services on behalf
Biomoda has entered into a final stage of patient testing in the phase II clinical trial of it’s early-stage diagnostic for lung cancer. The next stage of the
The Medicines company has announced that the Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion applicable to all Member States of the EU/European
BioCryst has announced that the FDA, has issued an Emergency Use Authorisation (EUA) for the investigational anti-viral drug intravenous iv Peramivir in certain adult and pediatric patients with
Exelixis and Bristol-Myers Squibb have reported updated phase 2 clinical data, which demonstrates XL184 activity in patients with glioblastoma multiforme (GBM). XL184 (BMS-907351) is an investigational oral inhibitor
Camfil Farr has been working closely with the capital projects team at Pfizer global research and development to help them realise significant savings on existing HVAC plant serving
Fuji Health Science, a nutraceutical and pharmaceutical bulk ingredient company, has extended its F-Melt and Fujicalin for the dietary supplement industry. F-Melt is compressible and designed for oral
UCB has reported its interim report for the first nine months of 2009. As expected, revenue declined in the first nine months of 2009 compared to the same
Novartis has maintained the strong underlying momentum of 2009 as third-quarter net sales grew 7% in local currencies, while reported net sales rose 3% to $11.1b as four